Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE versus STILBESTROL.
ESTRADIOL VALERATE vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, a natural estrogen. Estrogens exert their effects by binding to estrogen receptors (ERα and ERβ), which act as transcription factors regulating gene expression. This leads to proliferation and growth of reproductive tissues, modulation of gonadotropin secretion, and effects on bone density, lipid metabolism, and other tissues.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
1-2 mg orally once daily adjusted based on response; for hormone therapy, 5-20 mg intramuscularly every 4 weeks.
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 12-14 hours after intramuscular administration, allowing for weekly or biweekly dosing intervals.
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Renal (approximately 50% as glucuronide and sulfate conjugates), biliary/fecal (approximately 30-40% as conjugates), with enterohepatic circulation.
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category D/X
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."